Temps réel estimé
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
131,8 USD | +0,02 % | +6,57 % | +20,84 % |
Métier
- vente de produits pharmaceutiques (69,7%) : destinés au traitement de l'hypertension, de l'ostéoporose, de l'athérosclérose, des maladies respiratoires, bactériennes et fongiques, ophtalmologiques et urologiques, de la migraine aigue, de la perte de cheveux chez l'homme, etc. ;
- vente de vaccins (18%) ;
- vente de produits de santé animale (9,4%) ;
- autres (2,9%).
La répartition géographique du CA est la suivante : Etats-Unis (45,9%), Europe-Moyen Orient-Afrique (24,5%), Chine (8,8%), Japon (6,1%), Asie-Pacifique (6,1%), Amérique latine (4,3%) et autres (4,3%).
Nombre d'employés: 71 000
Ventes par activité
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Pharmaceutical
89,1
%
| 52 005 | 87,7 % | 53 583 | 89,1 % | +3,03 % |
Animal Health
9,4
%
| 5 550 | 9,4 % | 5 625 | 9,4 % | +1,35 % |
Other
1,5
%
| 1 728 | 2,9 % | 907 | 1,5 % | -47,51 % |
Ventes par région
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
United States
47,4
%
| 27 206 | 45,9 % | 28 480 | 47,4 % | +4,68 % |
Europe, Middle East and Africa
22,0
%
| 14 493 | 24,4 % | 13 254 | 22,0 % | -8,55 % |
China
11,3
%
| 5 191 | 8,8 % | 6 802 | 11,3 % | +31,03 % |
Asia Pacific
5,4
%
| 3 614 | 6,1 % | 3 225 | 5,4 % | -10,76 % |
Japan
5,3
%
| 3 629 | 6,1 % | 3 164 | 5,3 % | -12,81 % |
Latin America
5,1
%
| 2 582 | 4,4 % | 3 086 | 5,1 % | +19,52 % |
Other
3,5
%
| 2 568 | 4,3 % | 2 104 | 3,5 % | -18,07 % |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 01/04/14 |
Director of Finance/CFO | 55 | 01/01/90 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/08/20 |
Peter Dannenbaum
IRC | Investor Relations Contact | - | 01/07/17 |
Joseph Romanelli
IRC | Investor Relations Contact | 50 | 01/01/96 |
Johanna Herrmann
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | 01/01/21 | |
Andre Musto
PRN | Corporate Officer/Principal | - | 01/07/14 |
Carol Bowden
PRN | Corporate Officer/Principal | - | 01/04/14 |
James Matteucci
PRN | Corporate Officer/Principal | - | 01/01/03 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 27/11/07 |
Pamela Craig
BRD | Director/Board Member | 67 | 01/09/15 |
Inge Thulin
BRD | Director/Board Member | 69 | 01/03/18 |
Patricia Russo
BRD | Director/Board Member | 71 | 01/09/95 |
Peter Wendell
BRD | Director/Board Member | 73 | 23/09/03 |
Director/Board Member | 69 | 26/05/20 | |
Robert Davis
CEO | Chief Executive Officer | 57 | 01/04/14 |
Douglas Baker
BRD | Director/Board Member | 65 | 24/05/22 |
Stephen Mayo
BRD | Director/Board Member | 62 | 15/03/21 |
Kathy Warden
BRD | Director/Board Member | 52 | 16/03/20 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 3 578 114 121 | 2 530 196 240 ( 70,71 %) | 1 045 470 249 ( 29,22 %) | 70,71 % |
Participations
Nom | Actions | % | Valorisation |
---|---|---|---|
13 443 693 | 10,62% | 185 973 865 $ | |
1 739 768 | 5,21% | 23 017 131 $ | |
NGM BIOPHARMACEUTICALS, INC. 15,66% | 12 955 016 | 15,66% | 19 691 624 $ |
XILIO THERAPEUTICS, INC. 5,39% | 1 483 414 | 5,39% | 1 051 741 $ |
EVAXION BIOTECH A/S 12,13% | 2 297 884 | 12,13% | 827 238 $ |
Coordonnées société
Sociétés du groupe
Nom | Catégorie et Secteur |
---|---|
Pharmaceuticals: Major
| |
Organon (India) Pvt Ltd.
Organon (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology Organon India Pvt Ltd. manufactures and distribution of pharmaceutical preparations. The company is headquartered in Mumbai, India. |
Pharmaceuticals: Major
|
Dashtag
Dashtag Financial ConglomeratesFinance Founded in 1906, Dashtag is a part of Organon & Co. and operates an investment holding British company. The private company is based in Hoddesdon, UK. |
Financial Conglomerates
|
MSD Sharp & Dohme GmbH
MSD Sharp & Dohme GmbH Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD Sharp & Dohme GmbH develops and manufactures pharmaceutical products. The private company is based in Haar, Germany. The German company was founded in 1891. Chantal Friebertshäuser has been the CEO of the company since 2007. |
Pharmaceuticals: Major
|
Merck Holdings, Inc.
| |
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ. |
Pharmaceuticals: Major
|
Intervet India Pvt Ltd.
| |
Essex Chemie AG
| |
Merck Sharp & Dohme Finance Europe Ltd.
Merck Sharp & Dohme Finance Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 1993, Merck Sharp & Dohme Finance Europe Ltd. is a British company that provides business support services. Part of Merck & Co., Inc., the private company is based in Hoddesdon, UK. |
Miscellaneous Commercial Services
|
Secteur
Ventes par activité
Ventes par région
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
+20,84 % | 334 Md | |
+34,18 % | 701 Md | |
+26,24 % | 571 Md | |
+1,12 % | 381 Md | |
+17,07 % | 319 Md | |
+0,74 % | 210 Md | |
+2,95 % | 210 Md | |
-6,05 % | 201 Md | |
-2,55 % | 157 Md | |
-0,77 % | 153 Md |
- Bourse
- Actions
- Action Merck & Co., Inc. - Nyse
- Société Merck & Co., Inc.